ESG Report 2021

R&D Platform The Group has established the Chemical Research well-known experts in the Country and abroad, we Institute, the Biological Research Institute and the have organised and completed more than 70 clinical Department of Clinical Medicine to cooperate in trials of pharmaceuticals. At the same time, the research and development. The research institutes Group's Department of Research and Development are equipped with research talents and advanced also cooperates with universities to carry out equipment. Taking the Biological Research Institute research and development work to achieve better as an example, there are nearly 240 research and research and development results. development personnel, and the proportion of In order to actively expand the development of the personnel with graduate or above academic biopharmaceutical segment and optimise the internal qualification exceeds 30%. At the same time, it is resources of the Company, the Group established equipped with more than 100 large-scale research Zhuhai United Bio-Pharmaceutical Co., Ltd. ( 珠海聯 and development equipment with leading 邦生物醫藥有限公司 ) and The United Bio-Technology technologies in the Country and abroad. The (Hengqin) Co., Ltd. ( 聯邦生物科技 (珠海橫琴) 有限公 investment in assets exceeds RMB160 million. The 司 ) as our biopharmaceutical R&D companies. The Department of Clinical Medicine is responsible for Company will rely on its existing technology platform the design, organisation, implementation, quality and research team to expand investment in management and compliance and related work of all biological fields and high-end R&D talents. At clinical trial projects. It also closely cooperates with present, a number of products have entered different more than 100 domestic institutions with national stages of clinical and pre-clinical research, including drug clinical trial qualifications and authoritative diabetes drugs, monoclonal antibody drugs, animal treatment in related fields. Under the guidance of health and biomedicine, etc. RESEARCH AND DEVELOPMENT AND INNOVATION The Group continues to strengthen its investment in medications, autoimmune disease medications, R&D and innovation, build different pharmaceutical ophthalmic medications, veterinary medicines, etc. R&D platforms, and strive to develop and improve The production process and production technology more high-quality and safe drugs to make greater of drugs, environmental protection transformation contributions to human health. The direction of the and intelligent transformation are also one of the Group's research and development of drugs includes directions of R&D and innovation. We are committed new drugs and high-value generic drugs. Key to using better technology to provide our customers research and development areas involve endocrine with the best quality pharmaceutical products. 16 Environmental, Social and Governance Report 2021 The United Laboratories International Holdings Limited